ALDYSTRO Trademark

Trademark Overview


On Monday, April 18, 2022, a trademark application was filed for ALDYSTRO with the United States Patent and Trademark Office. The USPTO has given the ALDYSTRO trademark a serial number of 97368281. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Tuesday, November 5, 2024. This trademark is owned by Sarepta Therapeutics, Inc.. The ALDYSTRO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular d...
aldystro

General Information


Serial Number97368281
Word MarkALDYSTRO
Filing DateMonday, April 18, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, March 14, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations based on morpholino oligomer technology platform for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Pharmaceutical preparations that modulate RNA expression for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; Gene therapy products, namely, gene delivery pharmaceuticals; Pharmaceutical preparations for gene therapy, gene editing, and genome editing; Gene therapy products in the nature of pharmaceuticals for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Biological preparations for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Viruses, viral vectors and viral constructs for the treatment of neuromuscular diseases and disorders, muscular dystrophies, central nervous system diseases and disorders, genetic diseases and disorders; Pharmaceutical preparations, biological preparations and gene therapy products in the nature of pharmaceutical and biological preparations for the treatment of genetic disorders and diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 25, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSarepta Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Party NameSarepta Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02142

Trademark Events


Event DateEvent Description
Thursday, April 21, 2022NEW APPLICATION ENTERED
Monday, April 25, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, February 3, 2023ASSIGNED TO EXAMINER
Wednesday, February 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 22, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 14, 2023PUBLISHED FOR OPPOSITION
Tuesday, March 14, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 9, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, October 27, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 27, 2023SOU EXTENSION 1 FILED
Friday, October 27, 2023SOU EXTENSION 1 GRANTED
Tuesday, October 31, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, April 17, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, April 17, 2024SOU EXTENSION 2 FILED
Wednesday, April 17, 2024SOU EXTENSION 2 GRANTED
Tuesday, November 5, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, November 5, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 5, 2024SOU EXTENSION 3 GRANTED
Tuesday, November 5, 2024SOU EXTENSION 3 FILED
Thursday, April 18, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED